ClinicalTrials.gg
CompletedNCT03476798Clovis-001Updated Feb 15, 2024Results posted

Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

A Phase 2 interventional study of Rucaparib and Bevacizumab in Cervical Cancer and Endometrial Cancer, sponsored by University of Oklahoma. Completed at 3 sites in United States. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-02-15.

Sponsored by University of Oklahoma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing bevacizumab in Uterine Cervical Neoplasms — 1 open to participants now, 2 under way, 1 of them phase 3. Bevacizumab · Uterine Cervical Neoplasms.

Enrollment
8th of 16
49 · median 40
Started
2018
the only one that year
Phase 2
10 of 16
none open now
Registered
11th of 16
by date

Among the 16 studies testing bevacizumab in Uterine Cervical Neoplasms, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 10 in phase 2, and was the 11th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 680 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

1 of the 16 studies testing bevacizumab in Uterine Cervical Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 99 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing bevacizumab in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients with recurrent cervical or endometrial cancer. The objective of this study is to determine the proportion of these patients who survive progression-free for at least 6 months while receiving this drug combination.

Read the detailed description

Patients who consent to participate in this study will receive treatment with rucaparib and bevacizumab until unacceptable toxicity or tumor progression. Subjects will take one rucaparib pill will be taken twice daily, and bevacizumab will be adimistered via IV onDay 1 of each 21 day cycle. Subjects will receive tests and procedures that are part of regular cancer care as well as those required for the purposes of this study. If there is no cancer found in scans after 6 cycles of treatment, patients may continue with study treatment for 1 year. Follow up visits will occur every 3 months for the first 2 years after treatment is completed and every 6 months for 3 additional years.

03

Conditions studied

  • Cervical Cancer
  • Endometrial Cancer
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with -documented carcinoma of the cervix or endometrium.
  2. Patients with measurable and/or evaluable lesions as defined by 1.1.
  3. Women at least 18 years of age
  4. Patients with persistent or recurrent squamous cell or adenocarcinoma of the cervix, or any carcinoma or carcinosarcoma of the endometrium who has undergone at least one . Prior bevacizumab is allowed. (Note: previous cisplatin during radiation therapy should NOT count as a prior line of systemic therapy).
  5. performance status of 0, 1, or 2.
  6. Patients should agree to have tumor for correlative studies.If the patients are unable to be safely biopsied and desire enrollment, they may be enrolled per principal investigator discretion.
  7. Adequate organ function should be confirmed by the following laboratory values obtained ≤ 14 days prior to first dose of rucaparib.
  8. Patients must have a of at least 3 months ((to be able to complete one cycle of study treatment).
  9. Patients should have no major existing co-morbidities or medical conditions that will preclude therapy in the view of the principal investigator.
  10. Prior bevacizumab is allowed if off drug ≥ 28 days prior to study enrollment.
  11. Women of must not be considering getting pregnant and must avoid pregnancy during the study and for at least six months after the last dose of rucaparib or longer if requested by local authorities.

Exclusion criteria

Exclusion Criteria:

  1. Have active second , i.e., patient known to have potentially fatal cancer present for which she may be (but not necessarily) currently receiving treatment; However patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy was completed >6 months prior and/or bone marrow transplant (BMT) >2 years prior to first dose of rucaparib.
  2. Prior treatment with any PARP inhibitor.
  3. Untreated or symptomatic central nervous system (CNS) .Patients with asymptomatic are eligible provided they have been clinically stable for at least 4 weeks.
  4. Patients who have received treatment with chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C); or radiation, biologic/targeted agents, experimental drugs within 3 weeks prior to first dose of rucaparib; and/or ongoing adverse effects from such treatment > Grade 1 (Grade 2 non-hematologic toxicity to most recent treatment may be permitted with prior advanced approval from Sponsor).
  5. Hospitalization for bowel obstruction within 3 months prior to enrollment.
  6. Patients must have no history of gross hemoptysis (defined as bright red blood of a ½ teaspoon or more) or coagulopathy. Patients with history of major tumor-related bleeding that is not controlled despite locoregional treatment or at high risk of recurrent tumor-related bleeding will be excluded.
  7. Patients with history of hypertension must be well-controlled (≤150/100) on a stable regimen of anti-hypertensive therapy.
  8. Patients with tumors that invaded major vessels (e.g. the carotid) as shown unequivocally by imaging studies will be excluded due to the possibility of increased risk for tumor bleeding with bevacizumab therapy.
  9. Patients should not have a major surgical procedure, open , or significant traumatic injury within 28 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study. No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to registration. No serious non-healing wound, ulcer, or bone fracture.
  10. Patients should not have unstable angina or myocardial infarction within the previous 6 months; no uncontrolled hypertension; no symptomatic congestive heart failure; no serious cardiac arrhythmia requiring medication; no peripheral vascular disease; no history of any CNS cerebrovascular ischemia or stroke within the last 6 months; no active serious infection.
  11. Patients should not have other coexisting medical condition that would preclude full compliance with the study.
  12. Patients may not be receiving any other agents.
  13. Patients should not have a history of prior severe infusion reaction to a monoclonal antibody. Patients with known of Chinese hamster ovary cell products or other recombinant human antibodies.
  14. Pregnant women are excluded from this study because rucaparib and bevacizumab have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with rucaparib and bevacizumab, breastfeeding should be discontinued if the mother is treated with rucaparib and bevacizumab. Should a woman become pregnant or suspect she is pregnant while in this study, she should inform her treating physician immediately.
  15. -positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible drug interactions with rucaparib and bevacizumab.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Bevacizumab + Rucaparib

    Drug: Rucaparib · Drug: Bevacizumab

Interventions

  • Rucaparib 600mg PO BID daily

  • Bevacizumab 15mg/kg IV on day 1 of each cycle

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Who Are Progression-free at 6 Months

    To estimate the proportion of pts treated w/bevacizumab who are progression-free. Progression for measurable disease per RECIST v1.1. Progression for pts with non-measurable disease at baseline is defined as increasing clinical, radiological, or histological evidence of disease since study entry.

    Time frame: 6 months

Secondary outcomes

  1. Proportion of Patients Who Had Objective Tumor Response

    To estimate the proportion of patients treated with bevacizumab and rucaparib who have objective tumor response (complete or partial)

    Time frame: up to 2 years

  2. Number of Patients Who Experience Toxicity

    To determine the nature and degree of toxicity in combination of rucaparib and bevacizumab (Adverse Event Grade 3 and higher).

    Time frame: up to 2 year

  3. Median Overall Survival

    To estimate the median overall survival of patients treated with combination rucaparib and bevacizumab.

    Time frame: up to 2 years

  4. Median Progression-free Survival Time

    To estimate the progression-free survival (PFS) of patients with persistent or recurrent cervical or endometrial cancer treated with combination rucaparib and bevacizumab Progression for measurable disease per RECIST v1.1 Progression for patients with non-measurable disease at baseline is defined as increasing clinical, radiological, or histological evidence of disease since study entry.

    Time frame: up to 2 years

07

Results

Posted May 28, 2021

Participant flow

Participants were recruited at 3 cancer centers from June 2018 to Nov 2019. The first patient was enrolled on July 2, 2018 and the last patient was enrolled on November 8, 2019

Participant flow — Overall Study
MilestoneBevacizumab + Rucaparib
Started33
Completed28
Not completed5
Withdrew: Death1
Withdrew: Withdrawal by subject2
Withdrew: Protocol violation2

Outcome measures

PrimaryProportion of Patients Who Are Progression-free at 6 Months

To estimate the proportion of pts treated w/bevacizumab who are progression-free. Progression for measurable disease per RECIST v1.1. Progression for pts with non-measurable disease at baseline is defined as increasing clinical, radiological, or histological evidence of disease since study entry.

Time frame:
6 months
Reported as:
Number · Proportion of patients
Proportion of Patients Who Are Progression-free at 6 Months
Proportion of patientsBevacizumab + Rucaparib
Proportion of Patients Who Are Progression-free at 6 Months0.29 (0.13 to 0.47)
SecondaryProportion of Patients Who Had Objective Tumor Response

To estimate the proportion of patients treated with bevacizumab and rucaparib who have objective tumor response (complete or partial)

Time frame:
up to 2 years
Reported as:
Number · Proportion of patients
Proportion of Patients Who Had Objective Tumor Response
Proportion of patientsBevacizumab + Rucaparib
Proportion of Patients Who Had Objective Tumor Response0.14 (0.04 to 0.33)
SecondaryNumber of Patients Who Experience Toxicity

To determine the nature and degree of toxicity in combination of rucaparib and bevacizumab (Adverse Event Grade 3 and higher).

Time frame:
up to 2 year
Reported as:
Count of participants · Participants
Number of Patients Who Experience Toxicity
ParticipantsBevacizumab + Rucaparib
Number of Patients Who Experience Toxicity22
SecondaryMedian Overall Survival

To estimate the median overall survival of patients treated with combination rucaparib and bevacizumab.

Time frame:
up to 2 years
Reported as:
Median · Months
Median Overall Survival
MonthsBevacizumab + Rucaparib
Median Overall Survival10.12 (7.04 to 15.17)
SecondaryMedian Progression-free Survival Time

To estimate the progression-free survival (PFS) of patients with persistent or recurrent cervical or endometrial cancer treated with combination rucaparib and bevacizumab Progression for measurable disease per RECIST v1.1 Progression for patients with non-measurable disease at baseline is defined as increasing clinical, radiological, or histological evidence of disease since study entry.

Time frame:
up to 2 years
Reported as:
Median · Months
Median Progression-free Survival Time
MonthsBevacizumab + Rucaparib
Median Progression-free Survival Time3.83 (2.51 to 5.72)

Adverse events

Collected over up to 34 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab + Rucaparib29/33 (87.9%)14/33 (42.4%)33/33 (100%)
Most frequent serious events
Most frequent serious events
EventBevacizumab + Rucaparib
NauseaGastrointestinal disorders4/33
VomitingGastrointestinal disorders4/33
Acute kidney injuryRenal and urinary disorders3/33
Abdominal painGastrointestinal disorders2/33
FatigueGeneral disorders2/33
SepsisInfections and infestations2/33
Urinary tract infectionInfections and infestations2/33
DyspneaRespiratory, thoracic and mediastinal disorders2/33
Respiratory failureRespiratory, thoracic and mediastinal disorders2/33
Most frequent other events
Showing 10 of 60
Most frequent other events
EventBevacizumab + Rucaparib
NauseaGastrointestinal disorders21/33
FatigueGeneral disorders19/33
HypertensionVascular disorders19/33
DiarrheaGastrointestinal disorders16/33
VomitingGastrointestinal disorders16/33
HeadacheNervous system disorders15/33
DizzinessNervous system disorders11/33
CoughRespiratory, thoracic and mediastinal disorders11/33
ProteinuriaRenal and urinary disorders10/33
Urinary tract infectionInfections and infestations9/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bevacizumab + Rucaparib
Mean60.4 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab + Rucaparib
Female33
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bevacizumab + Rucaparib
Hispanic or Latino1
Not Hispanic or Latino32
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bevacizumab + Rucaparib
American Indian or Alaska Native2
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White27
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Bevacizumab + Rucaparib
United States33
08

Study locations

3 sites
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Stephenson Cancer Center, University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73117, United States
  • University of Virginia Cancer Center
    Charlottesville, Virginia 22903, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in May 2020, 22 months.

Results were first posted in May 2021, 1 year after primary completion.

Of 153 non-industry phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's 22 months is below that.

Counting every sponsor, half of 203 studies reached it within 42 months; a quarter within 29 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2018
First posted
Mar 26, 2018
StartActual
Jun 29, 2018
Primary completionActual
May 12, 2020
CompletionActual
Sep 29, 2023
Results first posted
May 28, 2021
Last update
Feb 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03476798
Collaborators
Clovis Oncology, Inc.
Responsible party
Sponsor
First posted
Mar 26, 2018
Start date
Jun 29, 2018
Primary completion
May 12, 2020
Completion
Sep 29, 2023
Results posted
May 28, 2021
Last update
Feb 15, 2024

Study contacts

Kathleen Moore, MD
principal investigator · Obstetrics and Gynecology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rucaparib · Bevacizumab

Start the discussion